Clinical Trial Update: Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma [Phase 2]

View source ↗

Summary

This document updates a Phase II clinical trial evaluating the combination of durvalumab and lenalidomide for relapsed/refractory extranodal natural killer/T-ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma Nasal Type

Drugs mentioned

• Durvalumab (durvalumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Singapore General Hospital | Conditions: LYMPHOMA | Phase 2 | Status: UNKNOWN